US6312948B1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Retroviral vector for the transfer and expression of genes for therapeutic purposes in eukaryotic cells
Assignee: Individual
•
Filing: 1999-11-03
•
Granted: 2001-11-06
•
Expires: 2019-11-03
Abstract
Abstract The invention relates to a recombinantvector for the cloning and/or expression and/or transfer of an exogenous nucleotide sequence characterized in that it consists of any sequence contained in the ClaI—PvuII fragment comprising nucleotides 7702 to 1527 of the sequence given in FIG. 1 and comprising the LTR sequence included between nucleotides 7842 and 144, the PBS site starting at nucleotides 145, the packaging sequence included in the sequences of 250 nucleotides following the end of the LTR sequence, the said sequence being capable of controlling the cloning and/or expression and/or transfer of the exogenous sequence whatever its transcriptional orientation with respect to the transcriptional orientation of the virus. It relates to the use of this vector for the transfer and/or cloning and/or expression of genes, in particular in the contest of gene therapy.
Inventors
- 👤 Odile Cohen-Haguenauer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 22:26
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/13011; C12N2740/13041; C12N2740/13043; C12N2830/00; C12N2830/32; C12N2830/80; C12N2830/85; C12N2840/00; C12N2840/20; C12N2840/203; C12N2840/206; C12N2840/44
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
72 words
A retroviral vector comprising an isolated nucleotide sequence comprising a 5′ long terminal repeat of Friend Murine Leukemia Virus, a primer binding site of Friend Murine Leukemia Virus, a packaging sequence of Friend Murine Leukemia Virus and a 3′ Long terminal repeat of a Friend Murine Leukemia Virus, wherein said vector comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO:12, and SEQ ID NO:13.
Claim 2
Dependent Claim
72 words
A retroviral vector comprising an isolated nucleotide sequence comprising a 5′ long terminal repeat of Friend Murine Leukemia Virus, a primer binding site of Friend Murine Leukemia Virus, a packaging sequence of Friend Murine Leukemia Virus and a 3′ Long terminal repeat of a Friend Murine Leukemia Virus, wherein said vector comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO:12, and SEQ ID NO:13.
Claim 3
Dependent Claim
17 words
The retroviral vector according to claim 1 , wherein the Friend Murine Leukemia Virus is strain FB29.
Claim 4
Dependent Claim
28 words
The retroviral vector according to claim 1 , wherein the retroviral vector lacks a nucleotide sequence encoding functional env and pol gene products of Friend Murine Leukemia Virus.
Claim 5
Dependent Claim
31 words
The retroviral vector according to claim 1 , wherein the isolated nucleotide sequence has a sequence from nucleotide position 7702 to nucleotide position 1527 of FIG. 1 (SEQ ID NO: 11).
Claim 6
Dependent Claim
31 words
The retroviral vector according to claim 1 , wherein the isolated nucleotide sequence has a sequence from nucleotide position 7806 to nucleotide position 1527 of FIG. 1 (SEQ ID NO: 12).
Claim 7
Dependent Claim
31 words
The retroviral vector according to claim 1 , wherein the isolated nucleotide sequence has a sequence from nucleotide position 7702 to nucleotide position 310 of FIG. 1 (SEQ ID NO: 13).
Claim 8
Dependent Claim
29 words
The retroviral vector according to claim 1 , further comprising a nucleotide sequence that encodes all or a portion of a gag gene product of Friend Murine Leukemia Virus.
Claim 9
Dependent Claim
37 words
The retroviral vector according to claim 7 , wherein the nucleotide sequence encoding a portion of the gag gene product has a sequence from nucleotide position 619 to nucleotide position 1031 of FIG. 1 (SEQ ID NO:16).
Claim 10
Dependent Claim
41 words
The retroviral vector according to claim 7 , wherein the nucleotide sequence encoding the portion of the gag gene product has a sequence from nucleotide position 619 to nucleotide position 1527 of the sequence shown in FIG. 1 (SEQ ID NO:15).
Claim 11
Dependent Claim
35 words
The retroviral vector according to claim 7 , wherein the nucleotide sequence encoding a gag gene product has a sequence from nucleotide position 619 to nucleotide position 2235 of FIG. 5 (SEQ ID NO: 14).
Claim 12
Dependent Claim
13 words
The retroviral vector of claim 1 , wherein said vector is a plasmid.
Claim 13
Dependent Claim
18 words
The retroviral vector of claim 11 , wherein the plasmid is pFOCH29 deposited with CNCM as No. I-1326.
Claim 14
Dependent Claim
48 words
The retroviral vector of claim 1 , further comprising at least one nucleotide sequence encoding a polylinker, wherein the polylinker has nucleotide sequence restriction sites not found in the isolated nucleotide sequence, and wherein the polylinker is located between the packaging sequence and the 3′ long terminal repeat.
Claim 15
Dependent Claim
23 words
The retroviral vector according to claim 1 , wherein the vector has a titer of about 10 4 PFU per ml. or greater.
Claim 16
Dependent Claim
22 words
The retroviral vector of claim 14 , wherein the vector has a titer of about 10 6 PFU per ml. or greater.
Claim 17
Dependent Claim
19 words
The retroviral vector according to claim 1 , further comprising a nucleotide sequence encoding an IntraRibosome entry site (iRES).
Claim 18
Dependent Claim
69 words
The retroviral vector according to claim 1 , wherein said 5′ terminal repeat of Friend Murine Leukemia Virus, said primer binding site of Friend Murine Leukemia Virus and said packaging sequence of Friend Murine Leukemia Virus are encoded by the nucleotide sequence of SEQ ID NO: 11, and said 3′ long terminal repeat of Friend Murine Leukemia Virus is encoded by the nucleotide sequence of SEQ ID NO: 13.
Claim 19
Dependent Claim
70 words
The retroviral vector according to claim 1 , wherein said 5′ long terminal repeat of Friend Murine Leukemia Virus, said primer binding site of Friend Murine Leukemia Virus and said packaging sequence of Friend Murine Leukemia Virus are encoded by the nucleotide sequence of SEQ ID NO: 12, and said 3′ long terminal repeat of Friend Murine Leukemia Virus is encoded by the nucleotide sequence of SEQ ID NO: 13.
Claim 20
Dependent Claim
25 words
The retroviral vector according to claims 17 or 18 , further comprising a polylinker sequence between said packaging sequence and said 3′ long terminal repeat.
Claim 21
Dependent Claim
26 words
The retroviral vector according to claim 19 , further comprising at least one exogenous nucleotide sequence encoding a polypeptide operably linked to the isolated nucleotide sequence.
Claim 22
Dependent Claim
69 words
A self inactivating retroviral vector comprising: an isolated nucleotide sequence comprising a 5′ long terminal repeat from Friend Murine Leukemia Virus, a primer binding site from Friend Murine Leukemia Virus, a packaging sequence from Friend Murine Leukemia Virus and a 3′ long terminal repeat of Friend Murine Leukemia Virus wherein the 3′ long terminal repeat has a deletion of the nucleotide sequences encoding the viral promoter and enhancer sequences.
Claim 23
Dependent Claim
69 words
A self inactivating retroviral vector comprising: an isolated nucleotide sequence comprising a 5′ long terminal repeat from Friend Murine Leukemia Virus, a primer binding site from Friend Murine Leukemia Virus, a packaging sequence from Friend Murine Leukemia Virus and a 3′ long terminal repeat of Friend Murine Leukemia Virus wherein the 3′ long terminal repeat has a deletion of the nucleotide sequences encoding the viral promoter and enhancer sequences.
Claim 24
Dependent Claim
43 words
The retroviral vector according to claim 21 , further comprising an expression cassette wherein the expression cassette is operably linked to the isolated nucleotide sequence and wherein the expression cassette comprises at least one exogenous nucleotide sequence operably linked to an exogenous promoter.
Claim 25
Dependent Claim
34 words
An Oligonucleotide primer sequence selected from the group consisting of: a. 5′ CTGCTGACGGGAGAAGAAAAAC-3 (SEQ ID NO:3); b. 5′ CCCGCTCAGAAGAACTCGTC-3′ (SEQ ID NO:4); c. 5′ GACGAGTTCTTCTGAGCGGG-3(SEQ ID NO:5); and d. 5′ GATCTGAACTTCTCTCTATTCTTG-3′ (SEQ ID NO:6).
Claim 26
Dependent Claim
34 words
An Oligonucleotide primer sequence selected from the group consisting of: a. 5′ CTGCTGACGGGAGAAGAAAAAC-3 (SEQ ID NO:3); b. 5′ CCCGCTCAGAAGAACTCGTC-3′ (SEQ ID NO:4); c. 5′ GACGAGTTCTTCTGAGCGGG-3(SEQ ID NO:5); and d. 5′ GATCTGAACTTCTCTCTATTCTTG-3′ (SEQ ID NO:6).
References Cited (Backward Citations)
US4650764A
Cited
WO1989011539A1
Cited
WO1990002797A1
Cited
WO1990006757A1
Cited
US5124263A
Cited
WO1991012329A2
Cited
WO1992005266A2
Cited
WO1994005780A1
Cited
EP0611822A2
Cited
EP0632129A1
Cited
FR2707091A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2004-11-05 | 2005-05-07 | 2005-11-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2008-11-05 | 2009-05-07 | 2009-11-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2012-11-05 | 2013-05-07 | 2013-11-06 | $7700.00 | Window Closed / Lapsed |